Trichome Financial Corp. entered into a binding letter agreement to acquire 22 Capital Corp. (TSXV:LFC.P) in a reverse merger transaction on October 2, 2018. Trichome and 22 Capital entered into a definitive amalgamation agreement on November 13, 2018. Pursuant to the deal terms, 22 Capital will effect a consolidation (the "Consolidation") of its common shares (the "Pre-Consolidation Shares") into such number of common shares ("Post Consolidation Shares") as is equal to the quotient obtained by dividing 1,495,000 by the Offering Price. 22 Capital will then acquire all of the issued and outstanding Trichome Shares on the basis of one Post-Consolidation Share for each Trichome Share outstanding. Prior to the completion of the transaction, Trichome intends to complete a brokered private placement of subscription receipts in an amount of CAD 15 million up to a maximum of CAD 30 million. Each Subscription Receipt will be automatically converted into one common share of Trichome immediately prior to completion of the transaction. In connection with the transaction, Trichome intends to complete a stock split of its outstanding Trichome Shares and preferred shares in each case on the basis of 1 share for 3 post-split shares. It is anticipated that, upon completion, the resulting issuer will be listed as a Tier 1 Investment issuer on the TSXV. Following closing of the transaction, and upon receipt of the Exchange's final acceptance, the common shares of the resulting issuer are expected to be listed on Tier 1 of the Exchange under the symbol "TFC". Subject to applicable shareholder and TSXV approval, it is anticipated that the Directors and thk officers of the resulting issuer will be: Marc Lustig, Chairman of the Resulting Issuer; Michael Ruscetta, Chief Executive Officer of the Resulting Issuer; Karl Grywacheski, Interim Chief Financial Officer of the resulting issuer, Kevin Jarrett, Vice President of Investments of the Resulting Issuer; Afzal Hasan, Director of the Resulting Issuer; Timothy Diamond, Director of the Resulting Issuer; Marissa Lauder, Director of the Resulting Issuer; Onekanew Christian Sinclair, Director of the Resulting Issuer; Jonathan Page, Director of the Resulting Issuer; Brent Cox, Director of the Resulting Issuer. Trichome Financial and 22 Capital revised the nominated list of Directors where Brent Cox and Afzal Hasan are withdrawn from nominees list and added Howard Steinberg as new Director nominee bringing the total as seven nominee Directors of the resulting issuer. As of June 3, 2019, under the terms of the transaction, the current management and directors of 22 Capital will resign and be replaced by a team consisting of Michael Ruscetta as Chief Executive Officer, Karl Grywacheski as Interim Chief Financial Officer and Kevin Jarrett as Vice President, Investments. The transaction is subject to customary closing conditions including entering into a definitive agreement, Trichome completing private placement, Trichome shareholder approval, regulatory approval, third party and lenders' consents. As of May 28, 2019, 22 Capital and Trichome have received conditional approval from the TSX Venture Exchange. The trading of 22 Capital's common shares will remain halted until 22 Capital receives the Exchange's final acceptance of the transaction. The annual special meeting of the shareholders of 22 Capital and a special meeting of the common and preferred shareholders of Trichome Financial will be held on July 4, 2019, wherein the shareholders will be asked to vote upon the transaction. As of June 3, 2019, the Boards of Directors of 22 Capital and Trichome Financial unanimously recommend the shareholders of 22 Capital to vote for the transaction. On July 8, 2019, 22 Capital Corp. and Trichome Financial Corp announced that the transaction is approved from the respective shareholders at the meeting of 22 Capital Shareholders on July 4, 2019 and the meeting of Trichome Financial Shareholders on July 8, 2019. As per amendment on February 13, 2019, the termination date for completion of the transaction is extended from January 31, 2019 to May 1, 2019. As per amendment on April 5, 2019, the termination date for completion of the transaction is extended from May 1, 2019 to July 31, 2019. As of May 28, 2019, the closing of the transaction is expected to take place on or around July 5, 2019 or such other date as 22 Capital and Trichome may agree. As of July 9, 2019, the transaction is expected to close on August 9, 2019. As of August 12, 2019, the transaction has been extended until August 30, 2019 by TSX Venture Exchange. As per amendment on September 19, 2019, the termination date for completion of the transaction is extended from August 30, 2019 to December 31, 2019. Janan Paskaran of Torys LLP acted as legal advisor for Trichome Financial Corp. Jay Goldman of Cassels Brock & Blackwell LLP acted as legal advisor for 22 Capital Corp. AST Trust Company, served as subscription receipt and escrow agent in connection with the private placement of subscription receipts of Trichome Financial. TSX Trust Company served as the registrar and transfer agent for 22 Capital Corp. Trichome Financial Corp. completed the acquisition of 22 Capital Corp. (TSXV:LFC.P) in a reverse merger transaction on October 4, 2019. Trichome Financial expects common shares to begin trading on TSX Venture Exchange on or about October 10, 2019 under the trading symbol "TFC".